NervGen Pharma Appoints Adam Rogers As New CEO (NVRV)

NervGen Pharmaceuticals (NVRV) announced on February 9, 2026, the appointment of Adam Rogers as its new Chief Executive Officer, effective March 1, 2026. The move follows the departure of the previous CEO, who stepped down to focus on a new venture. Rogers, currently President and COO, will lead the biopharmaceutical company as it advances its pipeline of therapies for rare neurological disorders. The company reported revenue of $12.5 million in 2024, with a strong focus on Phase III trials for its lead candidate, NVP-007.